Farouk Asmaa E, Fahmy Sohair R, Soliman Amel M, Ibrahim Sherif Abdelaziz, Sadek Shimaa A
Zoology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Appl Biochem Biotechnol. 2025 Jul 16. doi: 10.1007/s12010-025-05340-y.
Myocardial infarction (MI) is a concerning coronary heart disease with increasing rates of death and morbidity worldwide. One potential approach to prevent MI involves exploring invertebrate supplements within the nanoliposome formulation to improve targeted delivery, thereby mitigating MI-induced heart damage. Therefore, the study aimed to evaluate the cardioprotective efficacy of liposomal delivery of Allolobophora caliginosa coelomic fluid (ACCF-liposomes) on adrenaline-induced MI in rats. Thirty male albino rats were allocated into five groups: Control, Untreated MI, MI-treated ACCF, MI-treated free liposomes, and MI-treated ACCF-liposomes. The treatment regimen spanned 21 days. Electrocardiography (ECG), biochemical, oxidative stress, inflammatory mediators, electrolyte balance, histopathological and immunohistochemical analyses, and DNA fragmentation were evaluated. Liposomal delivery of ACCF has shown promise in regulating ECG criteria and reducing myocardial markers, particularly AST, LDH, MMP-2, creatine kinase, and troponin-I. It also improves lipid metabolism and inhibits myocardial oxidative stress. Additionally, ACCF and ACCF-liposomes treatment improves cardiomyocyte architecture and reduces DNA fragmentation in myocardial infarcted rats. Furthermore, encapsulating ACCF within liposomes statistically reduced the expression of iNOS and Beclin-1 in cardiac tissue. This suggests that liposomal delivery of ACCF enhances its effectiveness in treating myocardial infarction, potentially via its antioxidant, anti-inflammatory, and anti-apoptotic attributes.
心肌梗死（MI）是一种令人担忧的冠心病，在全球范围内死亡率和发病率不断上升。一种预防心肌梗死的潜在方法是探索纳米脂质体制剂中的无脊椎动物补充剂，以改善靶向递送，从而减轻心肌梗死引起的心脏损伤。因此，本研究旨在评估脂质体递送的黑暗异唇蚓体腔液（ACCF-脂质体）对肾上腺素诱导的大鼠心肌梗死的心脏保护作用。30只雄性白化大鼠被分为五组：对照组、未治疗的心肌梗死组、心肌梗死治疗的ACCF组、心肌梗死治疗的游离脂质体组和心肌梗死治疗的ACCF-脂质体组。治疗方案持续21天。评估了心电图（ECG）、生化、氧化应激、炎症介质、电解质平衡、组织病理学和免疫组织化学分析以及DNA片段化。ACCF的脂质体递送在调节心电图标准和降低心肌标志物方面显示出前景，特别是天冬氨酸转氨酶、乳酸脱氢酶、基质金属蛋白酶-2、肌酸激酶和肌钙蛋白-I。它还改善脂质代谢并抑制心肌氧化应激。此外，ACCF和ACCF-脂质体治疗改善了心肌梗死大鼠的心肌细胞结构并减少了DNA片段化。此外，将ACCF包裹在脂质体中在统计学上降低了心脏组织中诱导型一氧化氮合酶和Beclin-1的表达。这表明ACCF的脂质体递送增强了其治疗心肌梗死的有效性，可能是通过其抗氧化、抗炎和抗凋亡特性实现的。
